Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study

Benedikt M. Schaarschmidt, Roman Kloeckner, Thomas Dertnig, Aydin Demircioglu, Lukas Müller, Timo Alexander Auer, Daniel Pinto Dos Santos, Verena Steinle, Matthias Miederer, Bernhard Gebauer, Sonia Radunz, Stefan Kasper, Manuel Weber, Jens Theysohn

Abstract

Limited treatment options in patients with intrahepatic cholangiocarcinoma (iCCA) demand the introduction of new, catheter-based treatment options. Especially, 90Y radioembolization may expand therapeutic abilities beyond surgery or chemotherapy. Therefore, the purpose of this study was to identify factors associated with an improved median overall survival (mOS) in iCCA patients receiving radioembolization in a retrospective study at 5 major tertiary-care centers. Methods: In total, 138 radioembolizations in 128 patients with iCCA (female, 47.7%; male, 52.3%; mean age ± SD, 61.1 ± 13.4 y) were analyzed. Clinical data, imaging characteristics, and radioembolization reports, as well as data from RECIST, version 1.1, analysis performed 3, 6, and 12 mo after radioembolization, were collected. mOS was compared among different subgroups using Kaplan-Meier curves and the log-rank test. Results: Radioembolization was performed as first-line treatment in 25.4%, as second-line treatment in 38.4%, and as salvage treatment in 36.2%. In patients receiving first-line, second-line, and salvage radioembolization, the disease control rate was 68.6%, 52.8%, and 54.0% after 3 mo; 31.4%, 15.1%, and 12.0% after 6 mo; and 17.1%, 5.7%, and 6.0% after 1 y, respectively. In patients receiving radioembolization as first-line, second-line, and salvage treatment, mOS was 12.0 mo (95% CI, 7.6-23.4 mo), 11.8 mo (95% CI, 9.1-16.6 mo), and 8.4 mo (95% CI, 6.3-12.7 mo), respectively. No significant differences among the 3 groups were observed (P = 0.15). Hepatic tumor burden did not significantly influence mOS (P = 0.12). Conclusion: Especially in advanced iCCA, second-line and salvage radioembolization may be important treatment options. In addition to ongoing studies investigating the role of radioembolization as first-line treatment, the role of radioembolization in the later treatment stages of the disease demands further attention.

OriginalspracheEnglisch
ZeitschriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Jahrgang64
Ausgabenummer4
Seiten (von - bis)529-535
Seitenumfang7
ISSN0161-5505
DOIs
PublikationsstatusVeröffentlicht - 01.04.2023

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen
  2. SDG 9 – Industrie, Innovation und Infrastruktur
    SDG 9 – Industrie, Innovation und Infrastruktur

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Biomedizintechnik

DFG-Fachsystematik

  • 2.22-14 Hämatologie, Onkologie
  • 2.22-30 Radiologie
  • 2.22-33 Nuklearmedizin, Strahlentherapie, Strahlenbiologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren